Clinical trialRSSMay 14
Biotech raises $42 million to run Huntington’s disease trial
A biotech company called Latus Bio has raised $42 million in funding to support a clinical trial for Huntington's disease. This money will help them test a new treatment approach in patients with this genetic brain disorder. The funding shows that researchers are actively working on new ways to help people with Huntington's disease.
WHY IT MATTERSThis funding enables Latus Bio to move forward with testing their Huntington's disease treatment in patients, which could lead to new therapeutic options for people currently living with limited treatment choices.